IMNR.OB/IMRP.OB...is no longer valid. It has changed to "OCHT.OB"

[saffeysite1]

CARLSBAD, Calif.--(BUSINESS WIRE)--June 14, 2005--The Immune Response Corporation (Nasdaq:IMNR - News), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today that clinical research conducted by the Company in association with Oregon Health & Science University (OHSU) has indicated that FOXP3, a specific genetic marker on T-cells known to be involved in maintaining immune tolerance and regulation of autoimmune diseases, is significantly reduced in patients with MS compared to healthy controls. These findings, published in the July issue of the Journal of Neuroscience Research, are significant to the Company because this deficiency of FOXP3 in MS patients is likely linked to deficient numbers of regulatory T-cells (also known as Treg cells). The Company believes that induction of these Treg cells is important to the mechanism of action for NeuroVax(TM), the Company's peptide immune-based therapy.

Once this clears 0.98 the 200MA, should fly.  keep on watch.

[setravis]

Symmetrical Triangle.....Breakout.

The Immune Response Corporation Signs a $15 Million....

CARLSBAD, Calif., Jul 18, 2005 (BUSINESS WIRE) -- The Immune Response Corporation (IMNR, Trade), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, today announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with Cornell Capital Partners, LP, to support the continued development of the Company's product candidates. Under the agreement, which is generally referred to as an equity line of credit, Cornell Capital has committed to provide up to $15 million of funding to be drawn down over a 24-month period at the Company's discretion, subject to an effective registration. There are no minimum requirements on the draw downs in the SEDA agreement. The funds may be used in whole or in part as The Immune Response Corporation chooses.

John N. Bonfiglio, Ph.D., President and CEO of The Immune Response Corporation, said, "We are enthusiastic about entering into this agreement with Cornell Capital. The flexibility and control afforded by this capital structure will enable us to access capital at times when we believe the appropriate value is reflected in our stock price, as development milestones are achieved or when additional liquidity is necessary. The SEDA allows us to make financing decisions that we believe will be in the best interest of the Company and its shareholders."

Under Nasdaq rules, the Company will be required to obtain stockholder approval before drawing down the bulk of the SEDA funding. The Company will promptly seek such stockholder approval.

[setravis]

Volume increasing, up day

[setravis]

This one may have found a bottom.
Watch it now.......    
SOME NEWS OUT!!!!

[setravis]

Press Release Source: The Immune Response Corporation


The Immune Response Corporation Cleared to Initiate New IR103 Study in HIV Drug-Naive Patients in Italy
Tuesday September 27, 10:30 am ET 
IR103 Clinical Program Expands to 9 Sites in 3 Countries


CARLSBAD, Calif.--(BUSINESS WIRE)--Sept. 27, 2005--The Immune Response Corporation (Nasdaq: IMNR - News), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today it will begin enrolling patients, in Italy, in a Phase I/II study investigating IR103, the Company's newest product candidate for the treatment of HIV.


"The protocol for this study is designed to be compatible with part of the Phase I/II clinical trial currently underway in Canada and the UK so that the data can be jointly analyzed," said Georgia Theofan, Ph.D, vice president of clinical development at The Immune Response Corporation. "We are excited to be adding these six new sites to the IR103 clinical program which will now be active at nine sites in three countries."

The randomized, double-blind, comparative, multi-center Phase I/II study will begin enrolling patients this year and will follow them for 52 weeks. The primary objective is to evaluate safety and bioactivity, or the ability to generate HIV-specific immune responses to IR103, in HIV patients who have not initiated highly active anti-retroviral therapy (HAART). Ability to generate HIV-specific immune responses is thought to be an important indicator of clinical utility.

The patients, up to a total of 100, will be either newly enrolling patients or will be returning patients from a previous REMUNE® study. Patients previously treated with REMUNE® will be assigned across both tracks of the study enabling analysis of IR103 and REMUNE® in this patient population. The IR103 study track will evaluate and compare response to varying doses as well as placebo.

"Our strategies for REMUNE® and IR103 are complimentary with our drive to move REMUNE® into Phase III trials next year and IR103 continuing in Phase I/II. Both products are being investigated in HIV-positive, drug-naive patients and we believe they may be effective therapies throughout disease progression," remarked John N. Bonfiglio, Ph.D., president and chief executive officer of The Immune Response Corporation.

REMUNE® and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. IR103 combines the Company's patented HIV-1 immunogen with Amplivax(TM), an immunostimulatory oligonucleotide adjuvant. Amplivax(TM) was developed by Idera Pharmaceuticals and has been licensed to The Immune Response Corporation.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR - News) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and MS. The Company's HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax(TM), which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax(TM )or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax(TM )or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax(TM )or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004 and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation. Amplivax(TM) is a trademark of Idera Pharmaceuticals, Inc.



--------------------------------------------------------------------------------
Contact:
     The Immune Response Corporation
     Investor Contact:
     Michael K. Green, 760-431-7080
     [email protected]
     or
     Media Contact:
     Sam Brown Inc. Corporate Communications
     Laura Silver, 323-848-2051
     [email protected]



--------------------------------------------------------------------------------
Source: The Immune Response Corporation

[setravis]

MarketWatch
Market Pulse: Immune Response gets OK to start IR103 trial in Italy
Tuesday September 27, 10:39 am ET
By Carolyn Pritchard


SAN FRANCISCO (MarketWatch) -- Immune Response Corp. on Tuesday said it has received clearance to begin enrolling patients in a Phase I/II study in Italy investigating IR103, its newest product candidate for the treatment of HIV. The Carlsbad, Calif.-based biopharmaceutical company will start enrolling patients in the trial this year. A Phase I/II IR103 clinical trial is currently underway in Canada and the United Kingdom, Immune Response said.

[setravis]

Downtrending for some time.....
Could be ready to Rumble...... Back above the 13-dma.
Last Analyst Rating: Mkt Perform

[dwest718]

This thing has burned us four times ...  .  Haha maybe one more day of movement before more drop?

[setravis]

Have we found a bottom yet.......

[setravis]

Moving with nice volume.

[Terliso]

Good call setravis, let's trade this one tomorrow (applaud)

[Tequity]

As my first post I'll offer to take on the custodial matter of noting that this gem was moved to the OTC last November. 

I bought today because this stock traded on the Nasdaq just two months ago and closed at .08 today.. The market cap going from over $60 mil to $5 mil on no significant news looks like overkill. The CFO and former CEO both bought shares on the open market .46-.50 last September according to filings and the new CEO was given options for 6,000,000 shares exercisable at .32. Expecting at least a double from here.

[setravis]

Moving this morning....
+17.28%......Volume @......1,421,640

[setravis]

Move baby move.....
+43.21%.......Volume @.......2,846,904

[supergeek]

You know its a good sign when SE and Terlisa are on board. I jumped on for the last half of this run. Anyone have a target in sight?
Bob